

Ticagrelor (Fixed course)

Part 1: Information for patients



What is it used for?

Ticagrelor is used to help reduce the risk of further angina and heart attacks, especially after balloon angioplasty or stent insertion.

How does it work?

Ticagrelor helps to prevent blood clots from forming by stopping blood cells (platelets) sticking together.

How do I take it?

The normal dose is one tablet (90mg) taken twice a day, usually with food.

You should keep taking these tablets for _____ months.

Do not stop taking the tablets before the end of the prescribed course unless told to do so by your doctor.

Your cardiologist will tell you if you need to take them for longer.

The hospital has supplied the first part of the course. You should get the rest from your GP.

Are there any side effects

Ticagrelor can cause bleeding and stomach upsets. Contact your doctor if these are severe, or do not go away. It can also cause shortness of breath. If this happens, contact your doctor.

Further information

Further information is contained in the patient information leaflet enclosed in the ticagrelor (Brilique®) box. If you have any questions about this medicine or if you want to know more about any of your medicines, please speak to your doctor or pharmacist.



Ticagrelor (Fixed course)

Part 2: Information for doctors

(Please give to your GP)



Dear Doctor,

Your patient has been prescribed a course of ticagrelor treatment during a recent admission to hospital.

The duration of treatment is dependent on the diagnosis or type of coronary intervention performed.

Guidance on the duration of treatment is contained in the current version of the NHS Greater Glasgow & Clyde Antiplatelet Therapy in the Secondary Prevention of Coronary Heart Disease guideline.

The remaining course length for this patient is _____ months.

Treatment is therefore expected to stop on ____ / ____ / ____

Please annotate this discontinuation date on the prescription to help ensure the treatment is discontinued.

An initial **1 week / month** supply has been made. The patient will require a prescription for the remainder of the course.

Treatment should not be discontinued early unless as a result of a serious adverse drug reaction, and ideally after discussion with a cardiologist.

If you require any further information, please contact your patient's cardiologist or physician.